Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
ZYME 
Zymeworks Inc. Common Stock (ZYME)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/27/2025: ZYME (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -4.59% | Avg. Invested days 33 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 808.48M USD | Price to earnings Ratio - | 1Y Target Price 21.35 |
Price to earnings Ratio - | 1Y Target Price 21.35 | ||
Volume (30-day avg) 637396 | Beta 1.13 | 52 Weeks Range 7.97 - 17.70 | Updated Date 04/2/2025 |
52 Weeks Range 7.97 - 17.70 | Updated Date 04/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.62 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-03-04 | When Before Market | Estimate -0.0922 | Actual -0.31 |
Profitability
Profit Margin -160.8% | Operating Margin (TTM) -71.6% |
Management Effectiveness
Return on Assets (TTM) -14.57% | Return on Equity (TTM) -30.54% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 601213380 | Price to Sales(TTM) 10.6 |
Enterprise Value 601213380 | Price to Sales(TTM) 10.6 | ||
Enterprise Value to Revenue 8.14 | Enterprise Value to EBITDA 0.34 | Shares Outstanding 69576896 | Shares Floating 39116819 |
Shares Outstanding 69576896 | Shares Floating 39116819 | ||
Percent Insiders 0.19 | Percent Institutions 101.26 |
Analyst Ratings
Rating 4.38 | Target Price 20.44 | Buy 1 | Strong Buy 5 |
Buy 1 | Strong Buy 5 | ||
Hold 2 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Zymeworks Inc. Common Stock
Company Overview
History and Background
Zymeworks Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of next-generation multifunctional biotherapeutics. Founded in 2003, it focuses on developing novel treatments for cancer and other serious diseases. The company has evolved through various clinical trials and partnerships.
Core Business Areas
- Biotherapeutics Development: Focuses on the research and development of novel biotherapeutic drugs using their proprietary platforms.
- Technology Platform: Development and licensing of their Azymetricu2122 and EFECTu2122 platforms for biotherapeutic discovery.
Leadership and Structure
The leadership team comprises experienced professionals in biotechnology and drug development. The organizational structure includes research, development, clinical operations, and commercial functions.
Top Products and Market Share
Key Offerings
- Zanidatamab: A HER2-targeted bispecific antibody. Currently in clinical trials for various HER2-expressing cancers. Competitors include Roche (Herceptin, Perjeta), Seagen (Tukysa) and Daiichi Sankyo (Enhertu). Market share data not directly available as it is in clinical trials.
- ZW49: An antibody-drug conjugate (ADC) targeting HER2. Also in clinical trials. ZW49 is an ADC approach targeting HER2, competing with products like Enhertu from Daiichi Sankyo/AstraZeneca. Market share data not directly available as it is in clinical trials.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and dynamic, with continuous innovation and regulatory scrutiny. The oncology segment is particularly active, driven by unmet medical needs and advancements in drug development.
Positioning
Zymeworks is positioned as a leader in the development of multifunctional biotherapeutics, leveraging its proprietary technology platforms. Its competitive advantage lies in its ability to design and engineer novel antibodies with enhanced efficacy and safety profiles.
Total Addressable Market (TAM)
The TAM for cancer therapeutics is substantial, estimated to be in the hundreds of billions of USD annually. Zymeworks is focused on capturing a portion of this market with its innovative biotherapeutic candidates targeting specific cancer subtypes.
Upturn SWOT Analysis
Strengths
- Proprietary technology platforms (Azymetricu2122, EFECTu2122)
- Strong pipeline of biotherapeutic candidates
- Experienced management team
- Strategic partnerships with established pharmaceutical companies
Weaknesses
- Dependence on clinical trial outcomes
- High R&D expenses
- Competition from larger pharmaceutical companies
- Limited commercial infrastructure
Opportunities
- Potential for regulatory approval of lead candidates
- Expansion of pipeline through internal research and collaborations
- Out-licensing or partnering opportunities
- Increasing demand for novel cancer therapeutics
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from new and existing therapies
- Intellectual property challenges
Competitors and Market Share
Key Competitors
- Roche (RHHBY)
- Seagen (SGEN)
- Daiichi Sankyo (DSKYF)
- AstraZeneca (AZN)
Competitive Landscape
Zymeworks competes with established pharmaceutical companies and other biotechnology firms in the development of cancer therapeutics. Its advantages lie in its innovative technology platforms and pipeline of novel biotherapeutics.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Growth has been driven by advancements in clinical trials and expansion of the pipeline.
Future Projections: Future growth is dependent on regulatory approvals and successful commercialization of lead candidates. Analyst estimates vary based on clinical trial outcomes and market potential.
Recent Initiatives: Recent initiatives include advancing Zanidatamab and ZW49 through clinical trials, expanding collaborations, and exploring new therapeutic targets.
Summary
Zymeworks is a clinical-stage biopharmaceutical company with innovative technology and a promising pipeline. The company's future hinges on the success of its lead candidates in clinical trials and regulatory approvals. High R&D costs and competition pose challenges, but potential partnerships and market demand offer opportunities. The company's innovative Azymetric and EFECT platforms provides an edge.
Similar Companies
- RHHBY
- SGEN
- AZN
- MRNA
- GILD
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- Industry publications
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Investment decisions should be based on individual research and consultation with a financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Zymeworks Inc. Common Stock
Exchange NASDAQ | Headquaters Middletown, DE, United States | ||
IPO Launch date 2017-04-28 | Chairman of the Board, CEO & President Mr. Kenneth H. Galbraith C.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 280 | Website https://www.zymeworks.com |
Full time employees 280 | Website https://www.zymeworks.com | ||
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. The Zymeworks Inc. has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.